GB1528087A – Method of extracting a hyperglycemic factor
– Google Patents
GB1528087A – Method of extracting a hyperglycemic factor
– Google Patents
Method of extracting a hyperglycemic factor
Info
Publication number
GB1528087A
GB1528087A
GB48593/76A
GB4859376A
GB1528087A
GB 1528087 A
GB1528087 A
GB 1528087A
GB 48593/76 A
GB48593/76 A
GB 48593/76A
GB 4859376 A
GB4859376 A
GB 4859376A
GB 1528087 A
GB1528087 A
GB 1528087A
Authority
GB
United Kingdom
Prior art keywords
extraction
acetonic powder
acetonic
powder
buffered solution
Prior art date
1975-11-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB48593/76A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1975-11-21
Filing date
1976-11-22
Publication date
1978-10-11
1975-11-21
Priority claimed from FR7535645A
external-priority
patent/FR2332024A2/en
1975-11-21
Priority claimed from FR7535646A
external-priority
patent/FR2332025A1/en
1976-11-10
Priority claimed from FR7633847A
external-priority
patent/FR2370476A2/en
1976-11-22
Application filed by Individual
filed
Critical
Individual
1978-10-11
Publication of GB1528087A
publication
Critical
patent/GB1528087A/en
Status
Expired
legal-status
Critical
Current
Links
Espacenet
Global Dossier
Discuss
Classifications
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P3/00—Drugs for disorders of the metabolism
A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
Abstract
1528087 Hyperglycemic factor A THOMAS 22 Nov 1976 [21 Nov 1975 (2) 10 Nov 1976] 48593/76 Heading C3H A process for the preparation of a hyperglycemic factor, comprises treating red bone marrow either with water to form an aqueous extraction, or with acetone to form an “acetonic powder” as hereinbefore defined, and treating the filtered aqueous extraction or the acetonic powder, at a temperature from 60 to 100 C., with an alkaline buffered solution of pH 7À5 or an acid buffered solution of pH not greater than 4À0, adding alcohol to the resulting mixture, filtering it, and concentrating and/or purifying the resulting product. The extraction may be performed, not on the actual untreated ground material, but on an “acetonic powder” of red bone marrow. This acetonic powder is prepared by grinding the crushed red marrow directly at high speed in pure acetone (e.g. 1 kg red marrow pulp to 5 litres acetone), repeating the operation at least twice; the ground material is then strained to separate out residual bony particles, and finally dried. The alkaline buffered solution may be Na 2 HPO 4 , and the acid buffered solution is preferably an acetate solution. The extraction of acetonic powder is preferably performed using a 0À1 M phosphate buffer having a pH of 6À8, for example a mixture of disodium hydrogen phosphate and monopotassium phosphate may be used. The extract may be purified by precipitation, using ethanol, methanol, zinc acetate, methylalmethanol mixtures, to produce a supernatant layer containing a high concentration of the required compound. Extraction of the acetonic powder is preferably carried out using aqueous alcohol containing 5 to 80% alcohol, the acetonic powder itself being used as buffer. Alternatively the extract may be purified by cryoprecipitation.
GB48593/76A
1975-11-21
1976-11-22
Method of extracting a hyperglycemic factor
Expired
GB1528087A
(en)
Applications Claiming Priority (3)
Application Number
Priority Date
Filing Date
Title
FR7535645A
FR2332024A2
(en)
1975-11-21
1975-11-21
Hyperglycaemic factor from red bone marrow – which induces general glycogenolysis and elimination of sugar in the urine
FR7535646A
FR2332025A1
(en)
1975-11-21
1975-11-21
Hyperglycaemic factor from red bone marrow – which induces general glycogenolysis and elimination of sugar in the urine
FR7633847A
FR2370476A2
(en)
1976-11-10
1976-11-10
Hyperglycaemic factor from red bone marrow – which induces general glycogenolysis and elimination of sugar in the urine
Publications (1)
Publication Number
Publication Date
GB1528087A
true
GB1528087A
(en)
1978-10-11
Family
ID=27250554
Family Applications (1)
Application Number
Title
Priority Date
Filing Date
GB48593/76A
Expired
GB1528087A
(en)
1975-11-21
1976-11-22
Method of extracting a hyperglycemic factor
Country Status (11)
Country
Link
US
(1)
US4136170A
(en)
JP
(1)
JPS5315405A
(en)
AU
(1)
AU1979176A
(en)
DE
(1)
DE2652726A1
(en)
DK
(1)
DK523876A
(en)
ES
(1)
ES453470A1
(en)
GB
(1)
GB1528087A
(en)
IT
(1)
IT1067564B
(en)
LU
(1)
LU76235A1
(en)
NL
(1)
NL7613009A
(en)
SE
(1)
SE7612983L
(en)
Cited By (1)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
WO1981001367A1
(en)
*
1979-11-22
1981-05-28
Cell Eng Ag
A water soluble fraction capable of controlling the immune reactions of a host against allogeneic cells or tissue,the pharmaceutical compositions containing said fraction and a process for preparing the latter
Family Cites Families (1)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US2091730A
(en)
*
1934-08-06
1937-08-31
Armour & Co
Production of active concentrates
1976
1976-11-18
US
US05/742,908
patent/US4136170A/en
not_active
Expired – Lifetime
1976-11-19
DK
DK523876A
patent/DK523876A/en
unknown
1976-11-19
LU
LU76235A
patent/LU76235A1/xx
unknown
1976-11-19
AU
AU19791/76A
patent/AU1979176A/en
not_active
Expired
1976-11-19
ES
ES453470A
patent/ES453470A1/en
not_active
Expired
1976-11-19
DE
DE19762652726
patent/DE2652726A1/en
active
Pending
1976-11-19
IT
IT29520/76A
patent/IT1067564B/en
active
1976-11-19
SE
SE7612983A
patent/SE7612983L/en
unknown
1976-11-22
JP
JP13964176A
patent/JPS5315405A/en
active
Pending
1976-11-22
GB
GB48593/76A
patent/GB1528087A/en
not_active
Expired
1976-11-22
NL
NL7613009A
patent/NL7613009A/en
not_active
Application Discontinuation
Cited By (1)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
WO1981001367A1
(en)
*
1979-11-22
1981-05-28
Cell Eng Ag
A water soluble fraction capable of controlling the immune reactions of a host against allogeneic cells or tissue,the pharmaceutical compositions containing said fraction and a process for preparing the latter
Also Published As
Publication number
Publication date
DE2652726A1
(en)
1977-05-26
NL7613009A
(en)
1977-05-24
JPS5315405A
(en)
1978-02-13
DK523876A
(en)
1977-05-22
IT1067564B
(en)
1985-03-16
AU1979176A
(en)
1978-05-25
ES453470A1
(en)
1977-11-16
LU76235A1
(en)
1977-05-23
SE7612983L
(en)
1977-05-22
US4136170A
(en)
1979-01-23
Similar Documents
Publication
Publication Date
Title
EP0056268A1
(en)
1982-07-21
Process for the preparation of tobacco
BG61190B1
(en)
1997-02-28
Method for the preparation and/or purification of clavulanic acid and its pharmaceutically acceptable salt or ester
US4793996A
(en)
1988-12-27
Method of making soybean extract inhibitor
AU592727B2
(en)
1990-01-18
Purification of pertussis antigens
GB1528087A
(en)
1978-10-11
Method of extracting a hyperglycemic factor
Harington et al.
1931
The isolation of d-3: 5-diiodotyrosine from the thyroid gland by the action of proteolytic enzymes
CH643115A5
(en)
1984-05-30
PROCEDURE FOR DESALIFYING DISTILLERY RESIDUES.
US3201382A
(en)
1965-08-17
Process for preparing a biochemically active polypeptide from sheep pituitary growthhormone
JPS5688812A
(en)
1981-07-18
Preparation of phosphoric acid by wet process
Stoker et al.
1962
The isolation and identification of bound coumarin from Melilotus alba
EP0081831B1
(en)
1986-03-26
Process for purifying elastase
US2480991A
(en)
1949-09-06
Method of producing penicillin preparations
GB1240285A
(en)
1971-07-21
Purification of phosphoric acid
JPS5654225A
(en)
1981-05-14
Removal of selenium from sodium sulfate
DE3270983D1
(en)
1986-06-12
Process for preparing a mixture of bee pollen having an improved resorption capacity, and a hyposensibilizing mixture of bee pollen
JPH0659226B2
(en)
1994-08-10
Separation and recovery method of nosiheptide
ES8507440A1
(en)
1985-09-01
Fertilizer.
US2985561A
(en)
1961-05-23
Process for the producing of a substance which causes leucocytosis
US1725652A
(en)
1929-08-20
Process of extracting the cardio-active substance of bulbous scillae
RU2104940C1
(en)
1998-02-20
Method for extraction of rare-earth elements of ore concentrate of weathering crust of "kyndybai" deposit
US2909518A
(en)
1959-10-20
Recovery of vitamin b12
DE2139124C3
(en)
1974-11-21
Process for obtaining tetracycline
RU1832032C
(en)
1993-08-07
Method of insulin preparing
RU95109678A
(en)
1997-06-20
Method of system processing of leucoxene concentrate
DE2531519A1
(en)
1977-01-20
PROCESS FOR PROCESSING CRUDE PHOSPHATE
Legal Events
Date
Code
Title
Description
1979-01-31
PS
Patent sealed [section 19, patents act 1949]
1981-07-08
PCNP
Patent ceased through non-payment of renewal fee
